Lead Product(s) : Panobinostat lactate,Gadolinium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Luca Szalontay
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX110 (panobinostat) is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor), which is investigated for the treatment of Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2023
Lead Product(s) : Panobinostat lactate,Gadolinium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Luca Szalontay
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novocure
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Gadolinium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novocure
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bracco
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2020
Lead Product(s) : Gadolinium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bracco
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiac (CMRI) Assessment of Acromegaly
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2016
Lead Product(s) : Gadolinium
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase IV
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2015
Lead Product(s) : Gadolinium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase IV
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Research on Infarction With Open Arteries Using OCT and CMR
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2014
Lead Product(s) : Gadolinium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASIS for GAMMAGARD in Primary Immunodeficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2014
Lead Product(s) : Gadolinium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASIS for Enbrel in Plaque Psoriasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2014
Lead Product(s) : Gadolinium
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASIS for Botox in Upper Limb Spasticity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2014
Lead Product(s) : Gadolinium
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gadolinium
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASIS for Botox in Chronic Migraine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2014
Lead Product(s) : Gadolinium
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable